Navigation Links
Certain Diabetes Drugs May Pose Eye Risk
Date:4/7/2009

Use of Avandia, Actos tied to a retinal disorder, study finds

TUESDAY, April 7 (HealthDay News) -- A class of diabetes drugs called glitazones are associated with an increased risk of a vision-threatening complication called diabetic macular edema (DME), which features swelling and fluid accumulation in the retina.

Glitazones are a newer class of diabetes drugs that includes medicines such as pioglitazone (Actos) and rosiglitazone (Avandia).

The U.S. study of 996 DME patients found that those who took glitazones were 2.6 times more likely to develop DME than those who didn't take the drugs. Even after adjusting for other factors, the risk of DME remained 60 percent higher for patients who took glitazones, said the researchers at the Southern California Permanente Medical Group.

The study, published in the April issue of the American Journal of Ophthalmology, isn't the first to suggest a link between glitazones and DME. But it does confirm that the drugs are "modestly associated" with increased risk of DME, which is a common complication of diabetes.

"When treating patients with DME, ophthalmologists should consider the role of the glitazone class of drugs," the study authors concluded.

"Ocular (eye) complications are an overlooked safety issue of systemic drugs," noted Dr. Thomas J. Liesegang, editor-in-chief of the American Journal of Ophthalmology.

"Safety is as important as the efficacy of a drug. However, long-term safety is not currently monitored, because the approval process is based on smaller, shorter-term clinical trials. Safety necessarily requires monitoring of treatment in larger groups of people over longer periods of time. This monitoring is often neglected and should be required of all therapies," Liesegang said.

More information

The American Diabetes Association has more about diabetes-related eye complications.



-- Robert Preidt



SOURCE: Elsevier, news release, April 2, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Use of certain lipid measures not more effective in predicting coronary heart disease
2. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
3. MU researchers studying model to learn why certain cancers become resistant to drugs
4. New All-Natural Dietary Supplement Made from Muscadine Grape Skins Helps Inhibit Growth of Certain Cancers
5. Effectiveness of most PTSD therapies is uncertain
6. Value of Most Post-Traumatic Stress Treatments Uncertain
7. Certain Seizure Patients Need Emergency CT Scan
8. Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories
9. Certain Cholesterol Drugs Show Their Limits
10. ADHD Delays Growth of Certain Brain Areas
11. Stress hormone may hasten the progression of certain blood cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Certain Diabetes Drugs May Pose Eye Risk
(Date:12/6/2016)... ... 2016 , ... The Behavioral Health Center of Excellence (BHCOE) ... as a top behavioral service provider in the country. The award celebrates exceptional ... and qualifications, and consumer satisfaction. These areas are measured via a wide-ranging audit, ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... thrilled to formally announce its Not a Moment to Lose fundraising campaign. As ... rally supporters dedicated to declaring victory over cancer. The campaign aims to raise ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, one of ... particle counting and sizing services for USP 788 and 789 particulate standards compliance. ... as a response to the needs of pharmaceutical and medical device manufacturers, who ...
(Date:12/6/2016)... ... 06, 2016 , ... METTLER TOLEDO has launched its online ... white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user ... documents, webinars and videos available online, visit the METTLER TOLEDO Expertise Library ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder ... one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  BioAtla, ... the development of Conditionally Active Biologic (CAB) ... Beijing Sinobioway Group Company, Limited (Sinobioway) selected ... development.  The specific program candidates and the ... 2015, BioAtla and Sinobioway entered into a ...
(Date:12/5/2016)... 2016 United Kingdom Ophthalmic Diagnostic Equipment ... new report, "United Kingdom Ophthalmic Diagnostic Equipment Market ... the United Kingdom Ophthalmic Diagnostic Equipment market. The ... volume (in units) and average prices (USD) within ... Ultrasound Imaging Systems, Corneal Topography Systems, Ophthalmoscopes, Perimeters, ...
(Date:12/5/2016)... INTRODUCTION Since the ... as a crucial class of pharmacological interventions responsible ... are also used for prophylactic purposes in patients ... patients undergoing chemotherapy). However, the inappropriate use of ... rapidly accelerated an evolutionary response of antibiotic drug ...
Breaking Medicine Technology: